TAF2

Across TCGA pan-cancer cohorts, TAF2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TAF2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TAF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TAF2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, UCEC, and PDAC are the cancer types where TAF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.907	0.673	.006	21	view →
UCEC	DFS	Median	II,III,IV	0.882	0.493	.025	8	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
LUAD	OS	Tertile	III,IV	1.000	0.269	.005	6	view →
OV	DFS	Median	All	0.874	1.000	.047	4	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.897	.027	4	view →
CCRCC	OS	Median	All	0.846	0.954	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TAF2–LSCC (OS)

Open the LSCC breakdown →